Decision to Use
Made by physician or medical provider who has knowledge of the clinical situation and availability of compatible<unk>  components
Made in consultation with appropriate ancillary stakeholders to include<unk>  bank officer in charge, trauma director, chief of staff of the military treatment facility if circumstances permit otherwise follow previously established policy/procedures for field use
Limit use of FWB to indications noted above
Ensure FWB is type-specific matched to casualty
Annotate decision to use FWB in medical record
Precautions
No universal donor -- risk is reduced with use of low antibody titer type O<unk>  but not eliminated thus no true universal donor
Female casualties at or below child bearing potential should be Rh matched if possible to avoid antibody formation that may later cause harm<unk>  types on identification tags are known to be incorrect up to 10% of the time due to the fact that they are self-reported by the service member
Non-standard equipment may lead to coagulation during transfusion process
Planning Factors for FWB Donation Program
Establish robust pre-screen donor pool if possible
Rapidly establish ABO/Rh status of donors and casualties
Adhere to same screening, drawing, labeling, and issuing standards as for approved component products
Perform on-site testing of potential donors using rapid screening immunoassays then retrospective testing should be performed and documented in medical chart as well
Made by physician or medical provider who has knowledge of the clinical situation and availability of compatible<unk>  components
Made in consultation with appropriate ancillary stakeholders to include<unk>  bank officer in charge, trauma director, chief of staff of the military treatment facility if circumstances permit otherwise follow previously established policy/procedures for field use
Limit use of FWB to indications noted above
Ensure FWB is type-specific matched to casualty
Annotate decision to use FWB in medical record
No universal donor -- risk is reduced with use of low antibody titer type O<unk>  but not eliminated thus no true universal donor
Female casualties at or below child bearing potential should be Rh matched if possible to avoid antibody formation that may later cause harm<unk>  types on identification tags are known to be incorrect up to 10% of the time due to the fact that they are self-reported by the service member
Non-standard equipment may lead to coagulation during transfusion process
Establish robust pre-screen donor pool if possible
Rapidly establish ABO/Rh status of donors and casualties
Adhere to same screening, drawing, labeling, and issuing standards as for approved component products
Perform on-site testing of potential donors using rapid screening immunoassays then retrospective testing should be performed and documented in medical chart as well
Whole blood
Packed red blood cells
Dextrose
Fresh frozen plasma
Blood products
Methylene blue
Glucagon
N-Acetylcysteine